Nanobiotix

Nanobiotix is a late-stage clinical biotechnology company dedicated to pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. Their mission is to develop products that will transform outcomes for millions of cancer patients worldwide. Their lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to significantly increase the energy deposited by radiotherapy within tumor cells, thus destroying the target tumor and priming the immune response to attack metastatic tumors.

Their physics-based approach has the potential to overcome many of the challenges associated with traditional cancer therapy, including limitations in radiation dosing and resistance to treatment. Nanobiotix is focused on head and neck cancer initially, but believes that NBTXR3 has the potential to be effective across a range of solid tumor indications and treatment lines. They have a global clinical trial program and a partnership strategy that includes collaboration with The University of Texas MD Anderson Cancer Center and The Janssen Pharmaceutical Companies of Johnson & Johnson.

Nanobiotix, a late-stage clinical biotechnology company, is pioneering the development of physics-based nanotherapeutics to revolutionize cancer treatment. Their mission is to create innovative products that transform outcomes for millions of people fighting cancer worldwide by enhancing the effectiveness of radiotherapy while minimizing harmful side effects.

Nanobiotix promotes a culture of collaboration, innovation, and a shared commitment to improving patient outcomes. The company emphasizes the importance of pushing the boundaries of scientific research and developing disruptive technologies, fostered by a highly collaborative work environment that values individual contributions and encourages bold thinking. This culture is further reflected in Nanobiotix's dedication to working with world-class partners and institutions that share their vision of a future where cancer is less of a burden.

Nanobiotix is committed to fostering a diverse, equitable, and inclusive workplace. They believe that a diverse team, with a range of perspectives and backgrounds, is essential for driving innovation and achieving their mission of developing life-changing cancer treatments. The company strives to create a welcoming and supportive environment for all employees, where everyone feels valued and respected, regardless of their gender, ethnicity, race, sexual orientation, gender identity, disability, or any other characteristic. This is reflected in their commitment to equal opportunities, fair compensation, and a culture of inclusivity that encourages open communication and collaboration.